Literature DB >> 25308557

Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I.

Richard D Beegle1, Laurie M Brown, David A Weinstein.   

Abstract

Hepatocellular adenomas (HCAs) are a common complication in patients with glycogen storage disease type I (GSD I). In this series, we report regression of HCAs in a cohort of patients who achieved metabolic control with strict dietary therapy. A retrospective review of the clinical records for all patients with GSD I was performed at our institution. All available imaging studies were reviewed in patients with reported regression of HCAs in the medical record. The charts of 163 patients with GSD Ia and 42 patients with GSD Ib were reviewed, and HCAs were documented in 47 subjects (43 Ia/4 Ib). After review of all available imaging studies, eight patients met criteria of being followed with both magnetic resonance imaging and ultrasound and were found to show evidence of regression of HCAs. In these individuals, regression of the HCAs occurred once metabolic control was obtained, as determined by decreasing levels of serum triglyceride levels. The average triglyceride level in all patients prior to regression of HCAs was 753 mg/dL (SD ± 293). The average serum triglyceride level in all patients at the time of regression of HCAs was 340 mg/dL (SD ± 164). These findings suggest that strict dietary therapy may cause regression of HCAs. If HCAs are documented in a patient with suboptimal metabolic control, intensive medical therapy may be an alternative to surgical intervention in some individuals.

Entities:  

Year:  2014        PMID: 25308557      PMCID: PMC4361930          DOI: 10.1007/8904_2014_344

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  23 in total

1.  Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).

Authors:  Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit
Journal:  Eur J Pediatr       Date:  2002-08-22       Impact factor: 3.183

2.  Bland embolization in the treatment of hepatic adenomas: preliminary experience.

Authors:  Ajita Deodhar; Lynn A Brody; Anne M Covey; Karen T Brown; George I Getrajdman
Journal:  J Vasc Interv Radiol       Date:  2011-06       Impact factor: 3.464

3.  Natural history of hepatocellular adenoma formation in glycogen storage disease type I.

Authors:  David Q Wang; Laurie M Fiske; Caroline T Carreras; David A Weinstein
Journal:  J Pediatr       Date:  2011-04-09       Impact factor: 4.406

Review 4.  Glycogen storage disease type I: indications for liver and/or kidney transplantation.

Authors:  Philippe Labrune
Journal:  Eur J Pediatr       Date:  2002-07-19       Impact factor: 3.183

5.  Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease.

Authors:  David A Weinstein; Joseph I Wolfsdorf
Journal:  Eur J Pediatr       Date:  2002-07-31       Impact factor: 3.183

6.  Liver transplantation for glycogen storage disease type Ia.

Authors:  Srinevas K Reddy; Stephanie L Austin; Michele Spencer-Manzon; Dwight D Koeberl; Bryan M Clary; Dev M Desai; Alastair D Smith; Priya S Kishnani
Journal:  J Hepatol       Date:  2009-06-17       Impact factor: 25.083

7.  Hepatic adenomata in type Ia glycogen storage disease.

Authors:  C I Coire; A H Qizilbash; M F Castelli
Journal:  Arch Pathol Lab Med       Date:  1987-02       Impact factor: 5.534

8.  Percutaneous radiofrequency ablation of hepatocellular adenoma: initial experience in 10 patients.

Authors:  Hyunchul Rhim; Hyo K Lim; Young-Sun Kim; Dongil Choi
Journal:  J Gastroenterol Hepatol       Date:  2007-10-17       Impact factor: 4.029

9.  Hepatocellular carcinoma in type I glycogen storage disease.

Authors:  J Limmer; W E Fleig; D Leupold; R Bittner; H Ditschuneit; H G Beger
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

10.  Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy.

Authors:  P Parker; I Burr; A Slonim; F K Ghishan; H Greene
Journal:  Gastroenterology       Date:  1981-09       Impact factor: 22.682

View more
  14 in total

1.  Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.

Authors:  Gyongyi O Okechuku; Lawrence R Shoemaker; Monika Dambska; Laurie M Brown; Justin Mathew; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2017-06-13       Impact factor: 4.982

2.  Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.

Authors:  Jun-Ho Cho; Young Mok Lee; Matthew F Starost; Brian C Mansfield; Janice Y Chou
Journal:  J Inherit Metab Dis       Date:  2019-03-06       Impact factor: 4.982

3.  High Incidence of Serologic Markers of Inflammatory Bowel Disease in Asymptomatic Patients with Glycogen Storage Disease Type Ia.

Authors:  Nicole T Lawrence; Tayoot Chengsupanimit; Laurie M Brown; David A Weinstein
Journal:  JIMD Rep       Date:  2015-06-21

Review 4.  Studies on glycogen storage disease type 1a animal models: a brief perspective.

Authors:  Irina O Petrova; Svetlana A Smirnikhina
Journal:  Transgenic Res       Date:  2022-08-25       Impact factor: 3.145

Review 5.  Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.

Authors:  Teodoro Jerves; Nenad Blau; Carlos R Ferreira
Journal:  Mol Genet Metab       Date:  2022-03-28       Impact factor: 4.204

6.  Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.

Authors:  Katalin M Ross; Laurie M Brown; Michelle M Corrado; Tayoot Chengsupanimit; Latravia M Curry; Iris A Ferrecchia; Laura Y Porras; Justin T Mathew; David A Weinstein
Journal:  JIMD Rep       Date:  2015-08-25

7.  Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.

Authors:  Lauren R Waskowicz; Jin Zhou; Dustin J Landau; Elizabeth D Brooks; Andrea Lim; Zollie A Yavarow; Tsubasa Kudo; Haoyue Zhang; Yajun Wu; Stuart Grant; Sarah P Young; Bay Boon Huat; Paul M Yen; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2019-01-01       Impact factor: 6.150

Review 8.  Current Approaches in the Management of Hepatic Adenomas.

Authors:  Diamantis I Tsilimigras; Amir A Rahnemai-Azar; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Demetrios Moris; Eleftherios Spartalis; Jordan M Cloyd; Sharon M Weber; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-08-14       Impact factor: 3.452

9.  Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia.

Authors:  Joanne A Hoogerland; Fabian Peeks; Brenda S Hijmans; Justina C Wolters; Sander Kooijman; Trijnie Bos; Aycha Bleeker; Theo H van Dijk; Henk Wolters; Albert Gerding; Karen van Eunen; Rick Havinga; Amanda C M Pronk; Patrick C N Rensen; Gilles Mithieux; Fabienne Rajas; Folkert Kuipers; Dirk-Jan Reijngoud; Terry G J Derks; Maaike H Oosterveer
Journal:  J Inherit Metab Dis       Date:  2021-04-07       Impact factor: 4.982

10.  Glycogen storage disease type Ia: Adult presentation with microcytic anemia and liver adenomas.

Authors:  Wouter Moest; Wendy van der Deure; Ted Koster; Marcela Spee-Dropková; Linda Swart-Busscher; Robbert J de Haas; Terry G J Derks
Journal:  Hepatology       Date:  2018-04-27       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.